Enhancement characteristics of ultrasmall superparamagnetic iron oxide particle within the prostate gland in patients with primary prostate cancer

Journal of Computer Assisted Tomography

Volumn 32, Issue 4, 2008, Pages 523-528

  Li, Chao Shiang ^a,b   Harisinghani, Mukesh G ^a   Lin, Wen Chiung ^a,c   Braschi, Martha ^a   Hahn, Peter F ^a   Mueller, Peter R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Contrast media; Magnetic resonance imaging (MRI); Prostate cancer; Ultrasmall superparamagnetic iron oxide (USPIO)

Indexed keywords

ANTIGENS; BODY FLUIDS; CONTRAST MEDIA; DISEASES; IRON OXIDES; RESONANCE; SIGNAL TO NOISE RATIO; SUPERPARAMAGNETISM; UROLOGY;

CONTRAST MEDIUM; IRON OXIDE PARTICLES; MAGNETIC RESONANCE IMAGING; PROSTATE CANCERS; PROSTATE GLANDS; PROSTATE SPECIFIC ANTIGEN; SIGNAL-TO-NOISE RATIO DECREASE; T2 WEIGHTED; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

MAGNETIC RESONANCE IMAGING;

PROSTATE SPECIFIC ANTIGEN; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; IRON; OXIDE;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL NOISE RATIO; BLOOD; ENDOSCOPIC ECHOGRAPHY; EVALUATION; IMAGE ENHANCEMENT; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REPRODUCIBILITY; RETROSPECTIVE STUDY;

AGED; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBSERVER VARIATION; OXIDES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 49949086855     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e318136e194     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. Ann Oncol. 2006;56:106-130.
2. Cheng L, Jones TD, Lin H, et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol. 2005;174:2181-2185.
3. Squillaci E, Manenti G, Mancino S, et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res. 2005;24:523-530.
4. Swindle P, McCredie S, Russell P, et al. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology. 2003;228:144-151.
5. Shah N, Sattar A, Benanti M, et al. Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. J Am Osteopath Assoc. 2006;106:23-27.
6. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-2499.
7. Harisinghani MG, Saksena MA, Hahn PF, et al. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol. 2006;186:144-148.
8. Heesakkers RA, Futterer JJ, Hovels AM, et al. Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR imaging at 1.5 and 3.0 T: early experience. Radiology. 2006;239:481-487.
9. Nishimura H, Tanigawa N, Hiramatsu M, et al. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide. J Am Coll Surg. 2006;202:604-611.
10. Will O, Purkayastha S, Chan C, et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol. 2006;7:52-60.
11. Laghi A, Paolantonio P, Panebianco V, et al. Decrease of signal intensity of myometrium and cervical stroma after ultrasmall superparamagnetic iron oxide (USPIO) particles administration: an MR finding with potential benefits in T staging of uterine neoplasms. Invest Radiol. 2004;39:666-670.
12. Brillet PY, Gazeau F, Luciani A, et al. Evaluation of tumoral enhancement by superparamagnetic iron oxide particles: comparative studies with ferumoxtran and anionic iron oxide nanoparticles. Eur Radiol. 2005;15:1369-1377.
13. Taschner CA, Wetzel SG, Tolnay M, et al. Characteristics of ultrasmall superparamagnetic iron oxides in patients with brain tumors. AJR Am J Roentgenol. 2005;185:1477-1486.
14. Muldoon LL, Sandor M, Pinkston KE, et al. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery. 2005;57:785-796.
15. Turetschek K, Huber S, Floyd E, et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology. 2001;218: 562-569.
16. Fleige G, Nolte C, Synowitz M, et al. Magnetic labeling of activated microglia in experimental gliomas. Neoplasia. 2001;3:489-499.
17. Moore A, Marecos E, Bogdanov A Jr, et al. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology. 2000;214:568-574.
18. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging. 1994;4:301-307.
19. Bourrinet P, Bengele HH, Bonnemain B, et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol. 2006;41:313-324.
20. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology. 2006;239:784-792.
21. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:995-1000.
22. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274:1214-1220.
23. Oswald P, Clement O, Chambon C, et al. Liver positive enhancement after injection of superparamagnetic nanoparticles: respective role of circulating and uptaken particles. Magn Reson Imaging. 1997;15: 1025-1031.
24. Corot C, Petry KG, Trivedi R, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol. 2004;39:619-625.
25. Lutz AM, Weishaupt D, Persohn E, et al. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics. Radiology. 2005;234:765-775.
26. Allkemper T, Heindel W, Kooijman H, et al. Effect of field strengths on magnetic resonance angiography: comparison of an ultrasmall superparamagnetic iron oxide blood-pool contrast agent and gadopentetate dimeglumine in rabbits at 1.5 and 3.0 tesla. Invest Radiol. 2006;41:97-104.
27. Jain RK. Delivery of molecular medicine to solid tumors. Science. 1996;271:1079-1080.
28. Neuwelt EA, Varallyay P, Bago AG, et al. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol Appl Neurobiol. 2004;30:456-471.
29. Leung SY, Wong MP, Chung LP, et al. Monocyte chemoattractant proteinY1 expression and macrophage infiltration in gliomas. Acta Neuropathol (Berl). 1997;93:518-527.
30. Zhu P, Baek SH, Bourk EM, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell. 2006;124:615-629.
31. Vukanovic J, Isaacs JT. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res. 1995;55:1499-1504.
32. Zhang F, Lu W, Dong Z. Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice. Clin Cancer Res. 2002;8: 2942-2951.
33. Jimenez JA, Kao C, Raikwar S, et al. Current status of antiYangiogenesis therapy for prostate cancer. Urol Oncol. 2006;24:260-268.
34. Neuwelt EA, Várallyay CG, Manninger S, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery. 2007;60:601-611.
35. Tanimoto A, Yuasa Y, Shinmoto H, et al. Superparamagnetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function. Radiology. 2002;222:661-666.
36. Bugelski PJ, Kirsh RL, Sowinski JM, et al. Changes in the macrophage content of lung metastases at different stages in tumor growth. Am J Pathol. 1985;118:419-424.
37. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta. 1990;1032: 89-118.